Golimumab, a human anti-TNF antibody, is effective in patients with ulcerative colitis, according to new findings from an international phase III double-blind trial. The addition of this drug ...

Golimumab subcutaneous injectable solution is available as a brand-name drug. It’s not available as a generic drug. Brand name: Simponi. Golimumab comes in two injectable forms: a subcutaneous ...

Golimumab—a human monoclonal anti-TNF antibody—is effective for the treatment of patients with moderate-to-severe ulcerative colitis, according to new findings published in the journal ...

This is being followed by a period where participants are monitored but are not taking the drug. The Phase 2 study demonstrated that golimumab, an anti-tumor necrosis factor (TNF) therapy, reduced the ...

November 24, 2009 (San Diego, California) — A new fully human monoclonal antibody (MAb) against TNF, golimumab (CNTO148, Centocor/Schering-Plough), is close to entering the market. Results from ...

Golimumab (Simponi), taken with a drug called methotrexate, is recommended as a possible treatment for some adults with severe active rheumatoid arthritis in the same circumstances as other drugs for ...

This is being followed by a period where participants are monitored but are not taking the drug. The Phase 2 study demonstrated that golimumab, an anti-tumor necrosis factor (TNF) therapy, reduced the ...

Several controlled clinical trials have proven the efficacy of golimumab in reducing symptom severity and improving disease outcomes in patients with psoriatic arthritis. SAN FRANCISCO ...

The human monoclonal antibody golimumab (Simponi) preserved endogenous insulin secretion in patients with new-onset type 1 diabetes and reduced their exogenous insulin requirements at 1 year ...

In this phase 2 trial, children and young adults with newly diagnosed overt type 1 diabetes were randomly assigned to receive golimumab, a human monoclonal antibody to tumor necrosis factor α ...

Golimumab is a human monoclonal antibody specific for tumor necrosis factor α that has already been approved for the treatment of several autoimmune conditions in adults and children. Whether ...